ALX Oncology/$ALXO

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About ALX Oncology

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Ticker

$ALXO
Trading on

Industry

Biotechnology

Employees

65

ISIN

US00166B1052

ALX Oncology Metrics

BasicAdvanced
$29M
-
-$2.45
1.21
-

What the Analysts think about ALX Oncology

Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.

ALX Oncology Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALX Oncology Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALXO

Sign up or log in to buy
Capital at risk
Market openLow-cap

Upcoming events

FAQs

Can we use optional cookies? View our Cookie Policy for details.

pixel